MDXHEALTH
MDXH · NASDAQ
Updated at 2026-10-14 09:20:46
- Today's High
- $0.67
- Today’s Low
- $0.60
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $0.58
- Previous Close
- $0.60
- Volume
- 294.05K
- Market Cap
- $57.62M
- P/E Ratio
- --
- EPS
- $-0.88
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- DIAGNOSTICS & RESEARCH
- Headquarters
- CAP BUSINESS CENTER, HERSTAL, BELGIUM, 4040
- Country
- BE
- Listing Date
- 2006-06-26
- Fiscal Year End
- December
- Shares Outstanding
- 51.36M
- CIK
- 0001872529
- Website
- mdxhealth.com
MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, exemplifies the company's commitment to clinical efficacy and personalized medicine, establishing a strong foothold in a rapidly growing market. As the demand for targeted cancer therapies increases, MDxHealth is poised to expand its diagnostic offerings, effectively addressing critical unmet needs in oncology and improving patient outcomes. With its innovative solutions and strategic growth initiatives, MDxHealth is well-positioned to play a vital role in the future of cancer diagnostics.
Financial Metrics
Revenue
2026-06-30
$27.2M
2026-03-31
$54.66M
2025-12-31
$54.66M
2025-09-30
$27.43M
Operating Expenses
2026-06-30
$22.98M
2026-03-31
$40.87M
2025-12-31
$40.87M
2025-09-30
$20.51M
Net Income
2026-06-30
-$11.53M
2026-03-31
-$18.77M
2025-12-31
-$18.77M
2025-09-30
-$8.01M
Net Profit Margin
2026-06-30
-42.38%
2026-03-31
-34.34%
2025-12-31
-34.34%
2025-09-30
-29.19%
Earnings Per Share
2026-06-30
$-0.18
2026-03-31
$-0.17
2025-12-31
$-0.17
2025-09-30
$-0.16
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$1M
2026-03-31
-$6.89M
2025-12-31
-$6.74M
2025-09-30
$680K
Effective Tax Rate
2026-06-30
--
2026-03-31
5.17%
2025-12-31
5.17%
2025-09-30
0.07%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $27.2M | $54.66M | $54.66M | $27.43M |
| Operating Expenses | $22.98M | $40.87M | $40.87M | $20.51M |
| Net Income | -$11.53M | -$18.77M | -$18.77M | -$8.01M |
| Net Profit Margin | -42.38% | -34.34% | -34.34% | -29.19% |
| Earnings Per Share | $-0.18 | $-0.17 | $-0.17 | $-0.16 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$1M | -$6.89M | -$6.74M | $680K |
| Effective Tax Rate | -- | 5.17% | 5.17% | 0.07% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.